NT5C1A and inclusion body myositis: Further studies demonstrated a high reactivity of cN1A autoantibodies in 33–34% of IBM patients against low cross-reactivity in the control groups (4–5% PM, 0–4% DM, 0–3% neuromuscular disorders and 0% in healthy controls) [4,21].